公开(公告)号：US20080026012A1

公开(公告)日：2008-01-31

申请号：US11878460

申请日：2007-07-24

申请人： Eckhard Podack ,  Julie Spielman ,  Koichi Yamazaki

发明人： Eckhard Podack ,  Julie Spielman ,  Koichi Yamazaki

IPC分类号： A61K39/00 ,  A61K35/12 ,  A61P35/00 ,  A61P37/04

CPC分类号： A61K47/4833 ,  A61K38/00 ,  A61K39/385 ,  A61K47/646 ,  A61K47/68 ,  A61K2039/6043 ,  A61K2039/622 ,  C07K14/47 ,  C07K2319/00 ,  C07K2319/30 ,  Y02A50/403 ,  Y02A50/41 ,  Y02A50/466

摘要： The present invention relates to methods for purifying immunogenic, prophylactically and therapeutically effective complexes of modified heat shock proteins noncovalently associated with antigenic peptides of cancer or infected cells. The claimed methods comprise the constructing of a nucleotide sequence encoding a secretable modified heat shock protein, expressing the sequence in an appropriate host cell, recovering the immunogenic complexes from the cell culture and the cells, and purifying the immunogenic complexes by affinity chromatography. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the genetic sequence. The complexes can be used as a vaccine to elicit specific immune responses against cancer or infected cells, and to treat or prevent cancer or infectious diseases.

摘要翻译： 本发明涉及纯化与癌症或感染细胞的抗原肽非共价结合的修饰的热休克蛋白的免疫原性，预防和治疗有效复合物的方法。 要求保护的方法包括构建编码可分泌修饰的热休克蛋白的核苷酸序列，在合适的宿主细胞中表达该序列，从细胞培养物和细胞中回收免疫原性复合物，并通过亲和层析纯化免疫原性复合物。 通过大规模培养含有遗传序列的宿主细胞可以获得大量的这样的免疫原性复合物。 该复合物可用作疫苗以引发针对癌症或感染细胞的特异性免疫应答，以及治疗或预防癌症或感染性疾病。

公开(公告)号：US20070128184A1

公开(公告)日：2007-06-07

申请号：US11512412

申请日：2006-08-30

申请人： Eckhard Podack ,  Vadim Deyev ,  Robert Levy

发明人： Eckhard Podack ,  Vadim Deyev ,  Robert Levy

IPC分类号： A61K39/395 ,  C07K16/46 ,  C07K16/28

CPC分类号： A61K38/1709 ,  A61K35/13 ,  A61K39/0011 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/5152 ,  C07K16/241 ,  C07K16/2875 ,  C07K16/2878 ,  C07K2317/14 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76

摘要： It is an object of the invention to provide novel compositions and methods utilizing immunomodulating agents that can either stimulate or indirectly augment the immune system or in other cases have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used, among other things, to treat disease caused by asthma and chronic inflammation such as for example inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation. TNFR25 agonists disclosed herein represent biological response modifiers that alter the interaction between the body's cellular immune defenses and cancer cells to boost, direct, or restore the body's ability to fight the cancer when given with tumor vaccines. TNFR25 specific immunotoxins disclosed herein are also capable of increasing the effectiveness of a chemotherapeutic regimen by depleting a cancer patient of naturally occurring immunosuppressive cells.

摘要翻译： 本发明的一个目的是提供使用免疫调节剂的新型组合物和方法，其可以刺激或间接增强免疫系统，或在其它情况下具有免疫抑制作用。 本文公开的TNFR25激动剂具有抗炎和愈合作用。 它们可以用于治疗由哮喘和慢性炎症引起的疾病，例如包括溃疡性结肠炎和克罗恩病的炎症性肠病。 本文公开的TNFR25拮抗剂能够抑制CD8T细胞介导的细胞免疫应答，并且可以例如在组织移植后减轻器官或组织排斥。 本文公开的TNFR25激动剂表示改变身体的细胞免疫防御和癌细胞之间相互作用的生物反应调节剂，以在用肿瘤疫苗给予时增强，引导或恢复身体抵抗癌症的能力。 本文公开的TNFR25特异性免疫毒素还能够通过消耗天然存在的免疫抑制细胞的癌症患者来增加化疗方案的有效性。

公开(公告)号：US20080003221A1

公开(公告)日：2008-01-03

申请号：US10923373

申请日：2004-08-20

申请人： Eckhard Podack

发明人： Eckhard Podack

IPC分类号： A61K39/395 ,  A61K31/7105 ,  A61P11/00 ,  C12N5/06

CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K16/2875 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76

摘要： The invention provides a method of modulating a T cell immune response by modulating DR3 function in the T cell, wherein the T cell response causes a symptom of inflammatory lung disease. The invention also provides a method of treating a reactive airway disease in an animal subject by administering to the subject an agent which modulates at least one functional activity of CD30. The invention additionally provides a method for treating an inflammatory lung disease by administering an agent that decreases the activity of DR3 or CD30, whereby IL-13 expression is decreased.

摘要翻译： 本发明提供了通过调节T细胞中的DR3功能来调节T细胞免疫应答的方法，其中T细胞应答引起炎症性肺病的症状。 本发明还提供了通过向受试者施用调节至少一种CD30功能活性的药物来治疗动物受试者中的反应性气道疾病的方法。 本发明另外提供了通过施用降低DR3或CD30活性的药物来治疗炎症性肺病的方法，由此IL-13表达降低。

公开(公告)号：US20130052215A9

公开(公告)日：2013-02-28

申请号：US12580554

申请日：2009-10-16

申请人： Eckhard Podack

发明人： Eckhard Podack

IPC分类号： A61K39/12 ,  C12N5/22 ,  A61P35/00

CPC分类号： A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5156

摘要： The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject. The invention provides that a lung cancer cell or other tumor cells, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen, and method for stimulating an immune response to a tumor with the tumor cell so genetically modified. The invention additionally provides a method of inhibiting a tumor, including a cancer such as lung cancer, by administering an allogeneic tumor cell, for example a cancer tumor cell such as a lung cancer tumor cell, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen.

摘要翻译： 本发明涉及药物，免疫学和肿瘤学领域。 更具体地，本发明涉及用于在动物受试者中诱导针对肿瘤的免疫应答的方法和组合物。 本发明提供了经遗传修饰以表达编码CD80（B7.1）的核酸和编码HLA抗原的核酸的肺癌细胞或其它肿瘤细胞，以及用于刺激肿瘤细胞对肿瘤的免疫应答的方法 所以转基因 本发明还提供了一种抑制肿瘤的方法，包括癌症如肺癌，通过施用同种异体肿瘤细胞，例如经遗传修饰以表达编码CD80的核酸的癌症肿瘤细胞（例如肺癌肿瘤细胞） B7.1）和编码HLA抗原的核酸。

公开(公告)号：US20100119537A1

公开(公告)日：2010-05-13

申请号：US12580554

申请日：2009-10-16

申请人： Eckhard Podack

发明人： Eckhard Podack

IPC分类号： A61K39/12 ,  A61P35/00 ,  C12N5/22

CPC分类号： A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5156

摘要： The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject. The invention provides that a lung cancer cell or other tumor cells, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen, and method for stimulating an immune response to a tumor with the tumor cell so genetically modified. The invention additionally provides a method of inhibiting a tumor, including a cancer such as lung cancer, by administering an allogeneic tumor cell, for example a cancer tumor cell such as a lung cancer tumor cell, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen.

摘要翻译： 本发明涉及药物，免疫学和肿瘤学领域。 更具体地，本发明涉及用于在动物受试者中诱导针对肿瘤的免疫应答的方法和组合物。 本发明提供了经遗传修饰以表达编码CD80（B7.1）的核酸和编码HLA抗原的核酸的肺癌细胞或其它肿瘤细胞，以及用于刺激肿瘤细胞对肿瘤的免疫应答的方法 所以转基因 本发明还提供了一种抑制肿瘤的方法，包括癌症如肺癌，通过给予同种异体肿瘤细胞，例如经遗传修饰以表达编码CD80的核酸的癌症肿瘤细胞（例如肺癌肿瘤细胞） B7.1）和编码HLA抗原的核酸。

公开(公告)号：US20080233119A2

公开(公告)日：2008-09-25

申请号：US10923373

申请日：2004-08-20

申请人： Eckhard Podack

发明人： Eckhard Podack

IPC分类号： A61K39/395 ,  A61K31/7105 ,  A61P11/00 ,  C12N5/06

CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K16/2875 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76

摘要： The invention provides a method of modulating a T cell immune response by modulating DR3 function in the T cell, wherein the T cell response causes a symptom of inflammatory lung disease. The invention also provides a method of treating a reactive airway disease in an animal subject by administering to the subject an agent which modulates at least one functional activity of CD30. The invention additionally provides a method for treating an inflammatory lung disease by administering an agent that decreases the activity of DR3 or CD30, whereby IL-13 expression is decreased.

摘要翻译： 本发明提供了通过调节T细胞中的DR3功能来调节T细胞免疫应答的方法，其中T细胞应答引起炎症性肺病的症状。 本发明还提供了通过向受试者施用调节至少一种CD30功能活性的药物来治疗动物受试者中的反应性气道疾病的方法。 本发明另外提供了通过施用降低DR3或CD30活性的药物来治疗炎症性肺病的方法，由此IL-13表达降低。